Ignite Creation Date:
2025-12-25 @ 12:08 AM
Ignite Modification Date:
2026-06-25 @ 11:40 PM
Study NCT ID:
NCT05164458
Status:
RECRUITING
Last Update Posted:
2023-12-28
First Post:
2021-11-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies
Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Solid Tumors | View |
Keywords: